KAWASAKI, Japan – August 29, 2022 – Jiksak Bioengineering, Inc. (Jiksak), a biotechnology company focused on finding cures for amyotrophic lateral sclerosis (ALS) and peripheral nerve repair, today announced the closing of 800M JPY Series B investment led by CYBERDYNE, ANRI, the Cybernics Excellence Japan Fund 1 Investment Limited Partnership (CEJ Fund), operated by Cyberdyne Inc.’s subsidiary and Zeon Corporation, Inc.. Jiksak plans to use this latest funding to accelerate their research and development and to expand the business, focusing on ALS drug discovery and regenerative medicine.
